Saal Wiebke, Ross Alfred, Wyttenbach Nicole, Alsenz Jochem, Kuentz Martin
Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland , Gründenstrasse 40, 4132 Muttenz, Switzerland.
Institute of Pharmaceutical Technology, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland.
Mol Pharm. 2017 Apr 3;14(4):1243-1250. doi: 10.1021/acs.molpharmaceut.6b01116. Epub 2017 Mar 21.
The methacrylate-copolymer Eudragit EPO (EPO) has raised interest in solubility enhancement of anionic drugs. Effects on aqueous drug solubility at rather low polymer concentrations are barely known despite their importance upon dissolution and dilution of oral dosage forms. We provide evidence for substantial enhancement (factor 4-230) of aqueous solubility of poorly water-soluble anionic drugs induced by low (0.1-5% (w/w)) concentration of EPO for a panel of seven acidic crystalline drugs. Diffusion data (determined by H nuclear magnetic resonance spectroscopy) indicate that the solubility increasing effect monitored by quantitative ultraperformance liquid chromatography was caused primarily by molecular API polymer interactions in the bulk liquid phase. Residual solid API remained unaltered as tested by X-ray powder diffraction. The solubility enhancement (SE) revealed a significant rank correlation (r = -0.83) with rDiff, where SE and rDiff are defined ratios of solubility and diffusion coefficient in the presence and absence of EPO. SE decreased in the order of indomethacin, mefenamic acid, warfarin, piroxicam, furosemide, bezafibrate, and tolbutamide. The solubilizing effect was attributed to both ionic and hydrophobic interactions between drugs and EPO. The excellent solubilizing properties of EPO are highly promising for pharmaceutical development, and the data set provides first steps toward an understanding of drug-excipient interaction mechanisms.
甲基丙烯酸酯共聚物尤特奇EPO(EPO)已引起人们对提高阴离子药物溶解度的关注。尽管低聚合物浓度对口服剂型的溶解和稀释很重要,但其对水相药物溶解度的影响却鲜为人知。我们提供的证据表明,对于一组七种酸性结晶药物,低浓度(0.1 - 5%(w/w))的EPO可使难溶性阴离子药物的水溶解度大幅提高(4 - 230倍)。扩散数据(通过氢核磁共振光谱测定)表明,定量超高效液相色谱监测到的溶解度增加效应主要是由本体液相中分子活性药物成分(API)与聚合物的相互作用引起的。经X射线粉末衍射测试,残留的固体API未发生变化。溶解度增强(SE)与rDiff呈现出显著的等级相关性(r = -0.83),其中SE和rDiff分别是在有和没有EPO存在时溶解度和扩散系数的定义比值。SE按吲哚美辛、甲芬那酸、华法林、吡罗昔康、呋塞米、苯扎贝特和甲苯磺丁脲的顺序降低。增溶作用归因于药物与EPO之间的离子和疏水相互作用。EPO出色的增溶特性对药物开发极具前景,该数据集为理解药物辅料相互作用机制迈出了第一步。